Molnupiravir is an antiviral medication that has gained attention for its potential use in treating COVID-19 and other viral infections.
Molnupiravir is a prodrug, which means it is metabolized in the body into its active form. The active form of Molnupiravir works by inhibiting the replication of RNA viruses. It does this by causing mutations in the viral genetic material, which can lead to errors during viral replication and ultimately reduce the ability of the virus to reproduce.
Molnupiravir was originally developed as a potential treatment for influenza. However, its broad-spectrum antiviral activity has led to investigations into its effectiveness against other RNA viruses, including coronaviruses.
| Technical Parameter | Value |
|---|---|
| Generic Name | EIDD-2801 (2349386-89-4) |
| Indication | Treatment of COVID-19 (Cat FIP Treatment) |
| Country of Origin | China |
| Shipping Method | Air (UPS, FedEx, TNT, EMS) or Sea |
| Shelf Life | 2 years |
| Purity | 99% |
| CAS | 2349386-89-4 |
| COA | Available |
| Molecular Weight | 329.31 g/mol |
Molnupiravir, also known as MK-4482/EIDD-2801, is an antiviral medication with a unique mechanism of action. Its primary function is to inhibit viral replication by introducing errors during the copying process of the viral genetic material. Here's a breakdown of its function:
1. Inhibition of Viral Replication: Molnupiravir is a prodrug, which means it's metabolized in the body into its active form. Once inside the body, it is converted into a molecule that resembles one of the building blocks of RNA, the genetic material of the virus. When the virus attempts to replicate its RNA using these faulty building blocks, it introduces errors into its genetic code. This disrupts the virus's ability to make accurate copies of itself, thereby inhibiting its replication process.
2. Broad Spectrum Activity: Molnupiravir has shown effectiveness against a wide range of RNA viruses, including influenza viruses, coronaviruses (such as SARS-CoV-2), and other viruses like Ebola and Venezuelan equine encephalitis virus. This broad-spectrum activity makes it a promising candidate for the treatment of various viral infections.
3. Reduction of Viral Load: By inhibiting viral replication, Molnupiravir helps reduce the amount of virus present in the body, which can lead to milder symptoms and shorter duration of illness. This reduction in viral load may also contribute to lowering the risk of transmission to others.
1~25kgs packaging: Aluminium bag inside, Carton box outside.
25kgs packaging: Plastic bag inside, Fiber drum outside
